Inhalable mRNA With Ethris' Carsten Rudolph, Ph.D.
On the Business of Biotech, we welcome Carsten Rudolph, Ph.D., cofounder and CEO of Ethris, a company developing mRNA-based candidates for the treatment of respiratory viral infections and rare pulmonary diseases, in addition to mucosal, multivalent, and mutation-agnostic prophylactic vaccines. Rudolph explains the concept, the business case, and how he's navigating Ethris toward a better treatment and vaccine paradigm in the wake of the pandemic.
When should a brand become two brands? Charles River Associates provide analyses and case studies of dual brands to elucidate the pros and cons.
An industry observer with almost 50 years of experience shares some New Year's resolution wishes for the FDA and for industry, geared toward creating a foundation for sustainable quality in operations.
How mRNA Manufacturers Disrupt The Industry
See how biopharmaceutical companies can apply proven strategies to overcome hidden complexities in mRNA production and discover solutions that can help you rapidly design and build a SU facility.
CONTRIBUTE TO LIFE SCIENCE LEADER
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.
|Connect With Life Science Leader: